INTRODUCTION
Mesenchymal stem cells (MSCs) are mesodermal pro genitor cells that have a wide range of differentiation capacity. They can differentiate into adipocytes, osteo cytes, chondrocytes, myocytes, fibroblasts and stromal cells [1] . In addition, some research studies have shown that MSCs, under certain conditions, can transdifferentiate to cells from ectodermal and endodermal lineage [2, 3] . Among them, the ability of MSCs to develop into neurons is of particular interest. Considering that neural stem cells are limited in number and extremely difficult to be isolated while, comparatively, massive numbers of MSCs can be derived from numerous adult tissues, including, liver, kidney, adipose tissue, bone marrow, dental pulp, peripheral blood and umbilical cord blood. MSCs may serve as a reliable source of neural cells for potential cell replacement therapy or regenerative medicine.
Aside from its diverse differentiation capacity, their immunomodulatory properties also prompt researchers to study profoundly. MSCs are capable of regulating both innate and adaptive immunity. They secrete a large variety of soluble factors, including interleukin (IL)6, IL8, transforming growth factorβ1 (TGFβ1), indoleamine 2,3dioxygenase (IDO), human leukocyte antigenG (HLAG) and prostaglandin E2 (PGE2) [4] . These factors allow MSCs to interact with components of the innate and adaptive immunity, subsequently modulate inflammation and immune tolerance. Monocytes, for instance, under the influence of MSCssecreted IL6, IDO and PGE2, tend to develop into anti-inflammatory M2 macrophages instead of proinflammatory M1 macrophages [59] . In addition, recent reports showed that human gingiva derived MSCs have converted M1 macrophages to M2 [5] . Natural killer (NK) cells, on the other hands, express CD73 and acquires regulatory phenotype when exposed to MSCs [10, 11] . Similarly, regulatory dendritic cells (DC) induced by MSCs were capable of secreting IL-10, a powerful anti-inflammatory cytokine [1214] . Thus, MSCs are able to suppress innate immunity by skewing their differentiation into regulatory subtype ( Figure 1 ).
MSCs can regulate adaptive immune system by suppressing the proliferation, differentiation and activ ation of T cell and B cell. A number of studies have demonstrated that MSCs can inhibit the proliferation of Th1 and Th17 cell, decrease the production of interferon (IFN)γ, IL2, IL6 and IL17, and downregulate the T cell activation markers, CD38 and HLADR [1519] . When MSCs were cocultured with B cell and in the presence of different B cell trophic stimuli, B cell proliferation was inhibited and they were arrested in G0/G1 phase. Moreover, B cell differentiation was prohibited as indicated by limited production of IgG, IgM and IgA [20] . In addition, the regulatoryskewing propensity of MSCs observed in innate immune system also applies to T and B lymphocyte. In fact, the ability of MSCs to expand regulatory T (Treg) cells and regulatory B (Breg) cells have been intensively studied. However, the mechanism of how Treg and Breg cells are induced by MSCs has not been fully understood. Some suggest regulatory lymphocytes induction by MSCs requires mediation of other immune cells, while others propose MSCs-released cytokines are sufficient to expand Treg and Breg cell populations, but more and more researchers have come to the consensus that MSCs can use multiple pathways to generate regulatory lymphocytes and which pathways are more favorable is determined by the microenvironment that MSCs encounter [21] . Altogether, MSCs modulate immune cells to acquire regulatory phenotype, hence, alter the inflammatory milieu into a tolerogenic one (Figure 1 ).
There is another advantage of using MSCs for cellular therapy. MSCs have low immunogenicity, implying that MSCs can be used for allogeneic transplantation. This property is particularly helpful to the patient whose MSCs are compromised. Thereby, MSCs possess valu able therapeutic potential to treat immunemediated disorders [22] . Although MSCs have demonstrated as a promising immunoregulator for clinical use, the immunomodulatory and lowimmunogenicity properties of MSCs are not constitutive. The function of MSCs is based on the signals from the vicinity. MSCs, in the absence of tumor necrosis factor (TNF)a and IFNγ may adopt proinflammatory phenotype, which activate T cells to response. On the contrary, when MSCs are exposed to high level of TNFa and IFNγ they will behave as an antiinflammatory regulator by producing TGFβ1, IDO, and PGE2 [23] . Like wise, depending on the level of IL6, MSCs can convert monocyte into M1 or M2 macrophages [22, 2426] . Thus, before any clinical application, the plasticity of MSCs should be carefully considered. In this review, we summarized current understandings on how MSCs interact with regulatory lymphocytes, Treg and Breg cells particularly, to attenuate autoimmunity, and how this knowledge can contribute to therapeutic development.
Treg LYMPHOCYTE
The notion of "suppressive" T cells has long been pro posed in 1970s. Due to technical limitation, their identities and phenotypic characteristics cannot be described until 1995, Sakagucho et al [27] isolated a unique CD4 + CD25 + T cells that can suppress immune responses and maintain immunologic selftolerance [28] . Later, this subpopulation of T cells was named as Treg cells. For those Treg cells that undergo maturation in thymus, are referred to as thymus dervied Treg (tTreg) cells. Three days postmaturation, tTreg cells will relocate from thymus to periphery [29] . Surprisingly, tTreg cells only comprise 5%10% of peripheral T cells, but they are the critical regulator of autoimmunity. This is evidenced in mice lacking peripheral Treg cells. They were lethal due to various autoimmunity enhancements [29, 30] . Apart from tTreg cells, Treg cells can also be generated in periphery [31, 32] . [36] . In human, immune dysregulation, polyendo crinopathy, enteropathy, Xlinked syndrome (IPEX) is Xlinked recessive disorder caused by mutation in Foxp3 gene [37] . Treg cells from the patients with IPEX are either dysfunction or completely vanished. As a result, IPEX patients are afflicted with various autoimmune diseases, allergy and/or inflammatory bowel disease [38] . The provoked inflammation on IPEX patients indicates the failure of immune tolerance. Foxp3 promotes its regulatory effect by enhancing the expression of IL2 receptor (CD25), cytotoxic T cellassociated antigen4 (CTLA4), and glucocorticoidinduced TNF receptor familyrelated protein (GITR), meanwhile suppressing the production IL2, IL4 and IFNγ [39] . Treg cells monitor the inflammatory status by the exogenous level of IL-2. Binding of IL2 to CD25 would enhance the expression of Treg-cell associated genes and regulate the inflammation by suppressing effector T cell proliferation or by altering the function of antigen presenting cells [40] . Retroviral transfer of Foxp3 to naïve T cells (CD4
) can upregulate the expression of some Treg cellassociated genes, including CD25, CTLA4, GITR and CD103, and the Foxp3-transduced T cells were shown to be suppressive [41] . Altogether, Foxp3 is critical to the function and the development of Treg cells and to a greater extent, the maintenance of immune homeostasis [42, 43] .
Treg LYMPHOCTYE INDUCTION BY MSCs
MSCs are able to induce 
Secretion of soluble mediators
TGF-β1: MSCs can secrete TGFβ1 to promote Treg cell differentiation, especially when MSCs are placed in an inflammatory environment [21] . TGFβ1 is a potent immuno suppressor secreted by every leukocyte lineages, including macrophages, DCs, NK cells, T cells and B cells. Both TGFβ1 knockout mice and Tcell specific TGFβ receptor Ⅱ knockout mice develop severe autoimmunity, leading to multiple organs failure and death, suggesting the importance of TGFβ1 in regulating peripheral tolerance [44, 45] . Generally, TGFβ1 can suppress the proliferation of T cells, the activation of B cells, the maturation and antigen presentation of DCs, the cytotoxicity of NK cells, and phagocytic effect of macrophages [46] . Moreover, as mentioned earlier, TGFβ1 is able to convert naïve T cells to Foxp3 + Th3 cells, although such conversion seems to be concentrationdependent. High concentrations of TGFβ1 suppresses the expression of IL23R and shifts the conversion to Foxp3 + Th3 cells, whereas at lower concentrations and in the presence of IL6 and IL21, the expression of IL-23R is enhanced and results in RORγt + Th17 differentiation [47] . In addition, neutralizing TGFβ1 reduced mRNA and protein level of Foxp3 and CD25, further confirms its essential role in promoting Treg cell differentiation [48] . In conclusion, MSCssecreted TGFβ1 not only acts as a suppressor of innate and adaptive immune response, it can also induce development of Treg cells from naive T cells, which further enhance the regulatory effects.
PGE2:
MSCs can also secrete PGE2 to induce Treg cells. PGE2 plays a major role in suppressing chronic inflammation. PGE2 can reduce IFN-γ production of NK cells, limit the phagocytic ability of macrophages and interfere early activation of B cells [4952] . Although PEG2 can suppress early development of DCs, it is surprising that PGE2 also stabilize matured DCs and enhance its antigen presenting capacity [5355] . Moreover, despite PGE2 is able to shift the differentiation of naïve T cells from Th1 to Th2 cells, PGE2 also promote proinflammatory Th17 cell development by elevating IL23 production [56] . Thereby, PEG2 is not exclusively antiinflammatory. It also possesses the ability to provoke inflammation. Nevertheless, like TGFβ1, PGE2 can induce Foxp3 + Treg cell differentiation and it is one of many soluble medi ators that produce by MSCs. Diminishing PGE2 signaling when coculture CD4 + T cells with MSCs by antagonist indomethacin fail to upregulate Foxp3 and CD25 ex pression. In fact, when inhibiting both TGFβ1 and PGE2 signaling, the expression of Foxp3 and CD25 further decreased [48] . Furthermore, after transferring adipose tissuederived MSCs in asthmatic mice, the number of infiltrated inflammatory cells was significantly reduced and no obvious goblet cell hyperplasia was found in the lung. Meanwhile, the number of Treg cells was elevated. When TGFβ1 neutralizing antibodies or indomethacin was added to MSCstreated asthmatic mice, the anti inflammatory effects promoted by MSCs as well as the Treg cell expansion. These results demonstrated the necessity of TGFβ1 and PGE2 for Treg cell induction as well as the anti-inflammatory effect of MSCs [57] . IDO: IDO is a ratelimiting enzyme that catalyzes the degradation of tryptophan via kynurenine pathway. IDO is expressed in various cell types, including macrophages, DC and MSCs. Interestingly, IDO expression can be induced by IFNγ and other proinflammatory cytokines. Munn et al [58] treated pregnant mice carrying allogeneic or syngeneic fetus with 1methyltryptophan, an IDO inhibitor. As a result, allogeneic, but not syngeneic, fetuses provoked severe immune rejection [58] . Also, some studies suggested the association of tryptophan catabolism with inhibition of T cell proliferation, emphasizing its tolerogenic potential [59, 60] . In addition, kynurenines, a tryptophan catabolite, can promote Treg cell induction [61] . Infusion of MSCs to kidney allograft murine model prevented graft rejection, and the Treg cell population was elevated. In contrast, allograft tolerance and Treg cell expansion diminished when the recipients were treated with IDOdeficient MSCs. These results demonstrated the importance of IDO in MSCsmediated Treg cell induction and graft tolerance [62] . Other soluble factors, like human leukocyte antigenG5 and haem oxygenase 1, are also shown to be involved in MSCsmediated Treg cell induction [63, 64] . However, the underlying mechanisms are not clear. More studies need to be done in order to further increase the efficacy of MSCs-based therapy and to reveal the potential risk that could cause to the patients.
Cell-cell interaction
Apart from soluble mediators, cellcell interaction is also important to the modulatory function of MSCs and Treg cell induction. MSCs are known to express adhesion molecules on their surface, although only low level of expression can be detected in normal condition. However, after placing MSCs in inflammatory conditions, adhesion molecules, ICAM1 and VCAM1, chemokine ligands of CCR5 and CXCR3 are upregulated. Through these molecules, T cells are attracted and anchored to MSCs. With close proximity, adhesion molecules co operate with IDO and NO, suppress T cell activity by inducing their apoptosis or cell arrest [6568] . It is also worth to note that MSCs can inhibit the expression of ICAM1, CXCR3 and aintegrin on CD3 + T cell, reduced the interaction between T cells and endothelial cells, thus, disrupted T cells from infiltrating into CNS [69] . On the other hand, MSCs can attach to Th17 cells via CCR6 and CD11a/CD18 and facilitate Th17 to adopt regulatory phenotype [70] . Moreover, when coculture MSCs with CD4 + T cells in transwell system; Treg cells cannot be induced, even in the presence of PGE2 and TGFβ [48] . These results further confirmed cellcell interaction is essential to the overall suppressive effect of MSCs. However, Treg cell induction ability was recovered if MSCs were cocultured with peripheral blood mononuclear cells instead of isolated CD4 + T cells, suggesting there is an alternative pathway that does not require cellcell contact, and it is likely, through soluble mediators in peripheral blood mononuclear cells [48] .
Modulation of antigen presenting cells
Increasing evidence has indicated MSCs are able to shift macrophages, DCs and NK cells to a regulatory phenotype and alter their cytokines production. For example, MSCs skew monocyte toward M2 macrophage differentiation. Subsequently, M2 macrophages secrete CCL18 and IL10 to exert suppressive response and induce Treg cell differentiation [26] . As discussed above, IL10 is able to induce naïve T cell to Foxp3
Tr1 cell, which secrete high level of IL10 and TGFβ to modulate the inflammatory microenvironment. Interestingly, although MSCs express neither IL10 nor its receptor, MSCs are able to induce NK cells, DCs, macrophages, T cells and B cells to produce IL10 [5, 1012, 17] . In addition, IL10 is a powerful antiinflammatory cytokine that suppresses antigen-specific immune responses, reduces pathological immune responses and promotes allograft tolerance.
In conclusion, the mechanisms underlying MSCs mediated Treg cell development are complicated, which involve synthesis and secretion of multiple mediators, direct interaction with target cells and modulation of certain antigenpresenting cells. Apparently, there is no single pathway that governs the whole induction process, indicating that MSCs possess certain degree of plasticity. Regardless of how Treg cells are enhanced by MSCs, MSCsactivated Treg cells play a significant role on immunoregulation and affect a wide spectrum of immune responses [43, 71, 72] . Certainly, Treg cells can massively amplify the immunomodulatory effect of MSCs. However, the mechanism in regard to Treg cell induction is far from elaborate and additional researches are required.
Breg LYMPHOCYTE
In recent decade, Breg cells were being intensively investigated due to its immunosuppressive effect on excessive inflammation. Like Treg cells, Breg cells can produce antiinflammatory cytokines, like TGFβ and IL10. Among these, IL10 is strongly associated with Breg cells since depleting IL10producing B cells result in chronic inflammation, outgrowth of proinflammatory T cell after autoimmune induction [7375] . [79, 80] . Breg cells control infla mmation by suppressing IL12 secretion from DCs, thus inhibiting Th1 and Th17 differentiation [81] . Through the secretion of TGFβ, Breg cells can induce CD4 + T cell apoptosis and anergy in CD8 + cytotoxic T cells [82, 83] . Recent studies indicated that Breg cells play a role in Treg cell development and function. As Breg cells are one of the major sources of IL10, which drive Tr1 differentiation, it is not surprising that Breg cells can expand Treg cell population during inflammation. Additionally, when B cell specific IL10 defective mice (DBA/1IL10 KO / mice)
were induced with arthritis, the percentage of Tr1 was significantly decreased, indicating effects of IL10 + Breg cells on Treg cell formation [75] . Besides TGFβ and IL10, recent studies reported that IL35 is another pleiotropic cytokine that regulate overwhelming inflammation and autoimmunity [84, 85] . Antigendriven proliferation assay revealed that IL35 was able to suppress CD4 + T cell proliferation [86] . Treatment with IL35 ameliorated disease severity and reduced Th1 and Th17 cells in mice with experimental autoimmune uveoretinitis (EAU) [85] . More importantly, IL35 can increase Treg and Breg cell populations. Similar to IL10, IL35induced Treg (iTr35) cells are Foxp3
. However, adoptive transfer of iTr35 cells to various autoimmune disease animal models has sufficiently alleviated their clinical severity, and the effect was comparable to tTreg cellstreated mice [35] . On the other hand, when recombinant IL35 was injected into the EAU mice, the frequency of B220 + IL10 + Breg cells, IL 35 + Breg cells and B10 cells were upregulated in the spleen and draining lymph nodes [85] . Collectively, Breg cells exhibit anti-inflammatory and immunoregulatory effects, at least in part, by secreting multiple anti-inflammatory cytokines (TGFβ, IL10 and IL35), promoting differentiation of other regulatory cells, and inhibiting the proliferation and function of effector T cells.
Breg LYMPHOCYTE INDUCTION BY MSCs
Although MSCs do not constitutively express IL10, and currently there is no evidence to indicate that MSCs produce IL35, several studies have reported that MSCs induce IL10 + Breg cell differentiation in mouse model [8789] . Our group studied the effects of human bone marrowderived MSCs in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, and observed attenuation of clinical severity and neuroinflammation; and excitingly, these were associated with expansion of CD1d hi CD5 + Breg cells after MSCs administration [87] . Subsequently, another study demonstrated intravenous infusion of adipose tissue derived MSCs to Roquin san/san mice, an animal model of systemic lupus erythmatosus (SLE), lead to increased numbers of B10, B10pro and naïve Treg cells [89] . Moreover, the MSCsmediated Breg cell induction is not restricted to murine models. Administrating MSCs into refractory chronic graft vs host disease (cGvHD) patients have improved patients' overall clinical conditions. Consistent with murine models, MSCs increased the frequency and the function of CD5 + IL10 + Breg cells by enhancing their proliferation and survival [88] . Momentarily, we are still not clear about the mechanism regarding to MSCs 
THERAPEUTIC POTENTIAL OF GENETIC ENGINEERED MSCs
MSCs contain multiple properties that are suitable for therapeutical use. Widespectrum of differentiation capacity made it a perfect candidate for regenerative medicine. MSCs have been used to generate cartilage, bone, liver, intervertebral disc, and cardiac tissue [90] . Recent reports have suggested using MSCs for neural cell replacement. However, rather than direct neural differentiation, MSCs tend to recruit neural progenitor cells (NPCs) to the injury sites and support NPCs proliferation and differentiation [91] ; Immunomodulatory properties of MSCs are potentially useful for the treatment of autoimmune diseases and GvHD. Transplanted MSCs suppressed the proliferation and activation of T cells and NK cells in type 1 diabetes animal model. Also, the level of IFNγ and TNFa were reduced. When MSCs were cotransplanted with pancreatic islets, MSCs protected grafted islets from immunorejection and secreted various trophic factors to promote graft vascular network [92, 93] . Another intriguing advantage of using MSCs to treat immune diseases is that, unlike traditional immunotherapy in which a certain modulator act on a particular pathway, MSCs elicit their suppression on multiple immune cell types via various mechanisms. Although the immunosuppressive effects of MSCs appear very promising, further investigations are required to elucidate the underlying mechanisms, so as to prevent complications and maximize the therapeutic efficacy.
One current issue on immunotherapy is that a particular modulator or antibody may be seemingly effective, however, the therapeutic efficacy is limited since such modulator may also compromise certain cells or mediators beneficial to the disease recovery. Rituximab, for example, is a CD20 neutralizing antibody and it is believed to be an effective treatment for B and Tcellmediated diseases, such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus [9496] . Rituximabinduced Bcell depletion depends on the ex pression of CD20 on the cell surface, but the expression of CD20 gradually disappeared upon plasma cell diff erentiation [97, 98] . Moreover, Breg cells were also depleted, thus, exacerbates the disease symptoms [73] . In EAE, B10 cells play an important regulatory role during the initiative phase whereas they are less involved at the late phase of the disease [99, 100] . Therefore, depleting B cells by rituximab at the early phase have a potential risk of worsening the clinical conditions. As a consequence, it is necessary to develop an alternative strategy.
The immunosuppressive properties of MSCs on different murine autoimmune disease animal models support its potential clinical application. However, the immunomodulatory secretome of MSCs vary and greatly rely on the host inflammatory environment [21] . To mini mize this uncertainty, a novel therapeutic strategy, in which MSCs are genetically engineered with defined immunoregulatory cytokines, has been developed. Transplantation of IL10engineered adiposederived MSCs attenuated EAE by reducing the number of immune cell infiltration to the CNS, decreasing the secretion level of IL-17A, TNFa and IL2, and inhibiting antigenpresenting function of DC [101] . Since the immunosuppressive effect of MSCs is enhanced if they are placed proximal to the inflammatory area, Liao et al [102] engineered MSCs with CNS homing ligand genes, Pselectin glycoprotein (PSGL1) and SialylLewis x (SLeX), along with IL10 to EAE model. Consequently, EAE was attenuated, CNS homing ability was enhanced and their therapeutic efficacy was increased [102] . Genetic engineering of MSCs has been well studied in regenerative medicine. Different combination of treatments is documented and aims to redirect the MSCs differentiation propensity. Comparatively, genetic modification of MSCs for the treatment of autoimmune diseases is currently under development. Considering that the effect of MSCs may vary between patients with different severity of neuroinflammation, information on the clinical condition and pathology of the individual patient will probably help to predict treatment efficacy. Moreover, questions like in what phase of a particular disease introducing MSCs can improve the clinical outcome, or to what extent MSCs can elicit their suppressive effect and meanwhile, does not compromise the immunity in response to pathogens or infectious agents, are worthwhile to explore in order to safely use in human patients.
SAFETY AND CONCERNS OF MSCs AS CELLULAR THERAPIES IN PATIENTS
To date, there are nearly 500 ongoing MSCbased cli nical trials. They aim to investigate the effectiveness of MSCs on treating different diseases, including GvHD, diabetes, cardiovascular diseases, hematological diseases and neurological diseases [103] . Although most of these clinical trials reported the patients were well tolerated to the MSC infusion and administration, there are some safety concerns requiring caution [104] . During in vitro expansion, MSCs can give rise to replicative senescence, which may affect the activity of surrounding healthy cells and therefore, reduce the clinical efficacy [105] . Moreover, although MSCs have low immunogenicity due to the reduced expression of costimulatory receptors and major 
CONCLUSION
The immunomodulatory properties of MSCs have been massively studied due to its intriguing suppressive effects on various immunological diseases. Broadrange of immune cells can be regulated by MSCs through a series of soluble mediators stimulation, chemokine attraction, and celltocell interaction. MSCsinduced Treg and Breg cells enhance the immunosuppressive capacity and generate a tolerogenic microenvironment against overwhelmed inflammation. This hypothesis supports the observation that infused MSCs can only survive in the recipient for a short period of time, however, the regulatory effects of MSCs are long lasting, suggesting MSCs may act as an activator or a switcher that initiate certain cells, possibly Treg and Breg cells, to react to the inflammation and at the same time, alter the microenvironment for those cells to sustain their immunosuppressive effects. Although MSCs appear very promising as treatment in experimental models of autoimmune diseases, there are still many challenges need to overcome before MSCs can be widely use in clinical medicine.
